{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:22:40Z","timestamp":1702945360082},"reference-count":9,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1097\/hs9.0000000000000855","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T19:03:06Z","timestamp":1680721386000},"page":"e855","source":"Crossref","is-referenced-by-count":0,"title":["TP53 Mutations and Clinical Outcome in Chronic Lymphocytic Leukemia: Is a Threshold Still Needed?"],"prefix":"10.1002","volume":"7","author":[{"given":"Riccardo","family":"Bomben","sequence":"first","affiliation":[{"name":"Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano (PN), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Zucchetto","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano (PN), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Pozzo","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano (PN), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Tissino","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano (PN), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Bittolo","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano (PN), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacopo","family":"Olivieri","sequence":"additional","affiliation":[{"name":"Clinica Ematologica, Centro Trapianti e Terapie Cellulari \u201cCarlo Melzi\u201d DISM, Azienda Ospedaliera Universitaria S. Maria Misericordia, Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Chiarenza","sequence":"additional","affiliation":[{"name":"Division of Haematology, Ferrarotto Hospital, Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Zaja","sequence":"additional","affiliation":[{"name":"Department of Medical, Surgical and Health Sciences, University of Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Ilaria","family":"Del Principe","sequence":"additional","affiliation":[{"name":"Division of Haematology, University of Tor Vergata, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[{"name":"Haematology, Institute of Oncology Research, Bellinzona, Switzerland"},{"name":"Oncology Institute of Southern Switzerland, Bellinzona, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valter","family":"Gattei","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano (PN), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,4]]},"reference":[{"key":"R1-20231116","doi-asserted-by":"crossref","first-page":"e761","DOI":"10.1097\/HS9.0000000000000761","article-title":"Five percent variant allele frequency is a reliable reporting threshold for TP53 variants detected by next generation sequencing in chronic lymphocytic leukemia in the clinical setting.","volume":"6","author":"Pandzic","year":"2022","journal-title":"HemaSphere"},{"key":"R2-20231116","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41375-017-0007-7","article-title":"ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia - update on methodological approaches and results interpretation.","volume":"32","author":"Malcikova","year":"2018","journal-title":"Leukemia"},{"key":"R3-20231116","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1182\/blood-2013-11-539726","article-title":"Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.","volume":"123","author":"Rossi","year":"2014","journal-title":"Blood"},{"key":"R4-20231116","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1158\/1078-0432.CCR-20-4890","article-title":"Clinical outcomes in patients with multi-hit TP53 chronic lymphocytic leukemia treated with ibrutinib.","volume":"27","author":"Brieghel","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R5-20231116","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood.2020009530","article-title":"Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options.","volume":"138","author":"Malcikova","year":"2021","journal-title":"Blood"},{"key":"R6-20231116","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2015-07-659144","article-title":"Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.","volume":"127","author":"Nadeu","year":"2016","journal-title":"Blood"},{"key":"R7-20231116","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.1158\/1078-0432.CCR-21-0701","article-title":"TP53 mutations with low variant allele frequency predict short survival in Chronic Lymphocytic Leukemia.","volume":"27","author":"Bomben","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R8-20231116","doi-asserted-by":"crossref","first-page":"E168","DOI":"10.1002\/ajh.26127","article-title":"Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study [Published online 2021].","volume":"96","author":"Morabito","year":"2021","journal-title":"Am J Hematol"},{"issue":"S1","key":"R9-20231116","first-page":"285","article-title":"Interlaboratory comparison of NGS methods for detection of TP53 Variants <10% VAF: the first phase of an ERIC multicenter study on the clinical impact of low-frequent TP53 variants in CLL.","volume":"4","author":"Pavlova","year":"2020","journal-title":"HemaSphere"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HS9.0000000000000855","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T18:05:47Z","timestamp":1702922747000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HS9.0000000000000855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":9,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/hs9.0000000000000855","relation":{},"ISSN":["2572-9241"],"issn-type":[{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]}}}